# Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

> **NCT06940830** · PHASE4 · RECRUITING · sponsor: **Swedish Orphan Biovitrum** · enrollment: 250 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Efanesoctocog alfa

## Key facts

- **NCT ID:** NCT06940830
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-21
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940830, "Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06940830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*